Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hi-DoRi-3: High Dose Rifampicin for TB
NCT04485156Phase 3Not yet recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Sep 2020
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rifampicin in pulmonary tuberculosis (TB), sponsored by Seoul National University Hospital. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
rifampicin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT04485156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04485156.